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ABSTRACT 
The incidence of type 1 diabetes (T1D) is determined by both genetic and environmental 
factors. In recent years, the gut microbiota have been identified to be an important 
environmental factor that could modify diabetes susceptibility. We have previously shown 
that Myeloid differentiation primary response gene 88 (MyD88), a major adaptor protein 
downstream of most innate immune Toll-like receptor (TLR) signaling, is important for 
mediating diabetes susceptibility in the non-obese diabetic (NOD) mouse model of human 
T1D. Here we report the role of TIR-domain-containing adapter-inducing interferon-β (TRIF) 
in T1D development, as TRIF is an important adaptor protein downstream protected 
of TLR3 and TLR4 signaling. We found that TRIF-deficient (TRIF−/-) NOD mice were from 
development of diabetes, but only when housed with TRIF-deficient (TRIF−/-) NOD mice. 
When housed with TRIF-sufficient wild type (WT, i.e., TRIF+/+) NOD mice, the mice 
developed diabetes. We further investigated the gut microbiota as a potential cause for the 
altered diabetes development. Interestingly, TRIF−/−NOD mice had a different microbiota 
composition compared to WT NOD mice, only if they were housed with TRIF−/−NOD mice. 
However, the composition of gut microbiota in the TRIF−/−NOD mice was indistinguishable 
from WT NOD mice, if they were housed with WT NOD mice. The difference in the gut 
microbiota in TRIF−/−NOD mice, due to cohousing, accorded with the diabetes development 
in TRIF−/−NOD mice. Comparing the gut microbiota in TRIF−/- and WT NOD mice, we 
identified changes in percentage of Sutterella, Rikenella and Turicibacter species. Moreover, 
bacteria from WT NOD mice induced significantly stronger inflammatory immune response in 
vitro compared to those from TRIF−/−NOD mice. Further immunological analysis revealed 
impaired function of dendritic cellsand reduced T cell activation and proliferation in 
TRIF−/−NOD mice. Our data show that TRIF-deficiency protects NOD mice from diabetes 
development through alteration of the gut microbiota and reduced immune cell activation; 
however, that protection is over-ridden upon exposure to WT NOD bacteria. Therefore 
exposure to different microbiota can modify disease susceptibility determined by genetic 
factors related to innate immunity. 
 
INTRODUCTION 
Type 1 diabetes (T1D) is a T cell-mediated disease, which results in the progressive 
destruction of insulin-producing β cells in the pancreatic islets of Langerhans. Over the past 
few decades the incidence of T1D has risen and continues to do so [1,2] at a rate too fast to be 
attributed solely to genetic changes. Increasing evidence suggests that environmental factors 
contribute to the rise of T1D, and gut microbiota are an important modifier of diabetes 
susceptibility [[3], [4], [5], [6]]. The intestine has the largest surface area that is in direct contact 
with the environment, providing a site for many immune-microbe interactions. While some of 
the microbes are mutualistic and beneficial to the host, others can be detrimental. This 
balance (homeostasis) between host and microbes is critical for maintaining good health. 
 
Toll-like receptors (TLRs) are pattern-recognition receptors, which play a crucial role in 
initiating the innate immune response to microbes to both fight infection and maintain 
homeostasis. There are many different TLRs, all of which bind to different pathogen 
associated molecular patterns. TLR4 binds lipopolysaccharide (a major cell wall component 
of gram-negative bacteria) [7] and this leads to the activation of two major adaptor molecules 
that mediate downstream TLR signaling – the myeloid differentiation primary response gene 
88 (MyD88) and the TIR-domain-containing adapter-inducing interferon-β (TRIF). While most 
TLRs signal through MyD88, TLR3 that detects viruses and TLR4 can both signal 
through TRIF [8]. 
 
Recent studies suggest that the gut microbiome can be linked to various diseases 
including autoimmune diseases, cancer and inflammatory bowel disease [9]. We previously 
reported that T1D susceptibility was modified by the gut microbiota in MyD88-deficient non-
obese diabetic (NOD) mice [3]. Further, studies have shown that different microbial-sensing 
TLRs have different effects on the development of T1D [[10], [11], [12], [13], [14], [15]]. T1D 
development in TLR3-deficient NOD mice is similar to TLR3-sufficient NOD mice [11] but 
reduced in a virus-induced model system [16]. However, T1D development is increased in 
TLR4-deficient NOD mice [3,12], although both TLR3 and TLR4 signal through TRIF. To 
investigate the role of TRIF in spontaneous autoimmune diabetes development and its effect 
on the gut microbiota, we generated TRIF-deficient (TRIF−/−) NOD mice. Our results showed 
that NOD mice are protected from diabetes development in the absence of TRIF. However, 
this protection from diabetes was not observed if TRIF-deficient NOD mice were housed with 
TRIF-sufficient mice. Furthermore, we demonstrated that the protection from disease was 
associated with alterations in the composition of gut microbiota. In addition to the important 
role that the gut microbiota play in T1D development in TRIF−/−NOD mice, TRIF deficiency 
also alters the function of dendritic cells (DCs) and T cells including regulatory T cells (Treg). 
Interestingly, the effect of TRIF deficiency on the immune cells can be overcome when 
introducing gut microbiota from TRIF-sufficient mice, illustrating the importance of both genes 
and environmental interactions in mediating diabetes susceptibility 
 
2. MATERIALS AND METHOD 
2.1. Mice 
NOD/Caj mice were originally obtained from the Jackson Laboratory and have been 
maintained at Yale University for over 30 yrs. TRIF-deficient (TRIF−/-) NOD mice were 
generated by backcrossing TRIF−/-C57BL/6 mice (C57BL/6J-Ticam1Lps2/J purchased from 
the Jackson Laboratory) to our NOD/Caj mice, which are wild type (+/+) for the TRIF gene. 
The progeny of this breeding was designated as N1, which are all heterozygous, +/−, for the 
TRIF gene. N1 mice were then bred again with our NOD/Caj mice to generate N2, which 
have progeny heterozygous for the TRIF knockout gene (±) or wild type (+/+). We selected 
N2 mice with TRIF+/− genotype to further backcross to our NOD/Caj mice to obtain N3. We 
repeated this back cross to our NOD/Caj mice for over 10 generations. We then intercrossed 
the N11 mice with the TRIF+/− genotype (N11 × N11) to generate the progeny with TRIF+/+, 
TRIF+/- and TRIF−/- genotypes, designated as TRIF+/+ NOD, TRIF+/- NOD and TRIF−/- 
NOD mice. To ensure the NOD genetic purity, two randomly selected TRIF−/- NOD mice, 
which were analyzed for SNPs throughout the mouse genome (DartMouse, Lebanon, NH). 
SNP genome analysis revealed that there was no evidence of non-NOD genomic regions 
except for the targeted TRIF locus. TRIF+/+NOD and TRIF−/ −NOD mice were used in the 
study and for cohousing experiments, TRIF+/+ NOD and TRIF−/−NOD mice were littermates 
that were generated from TRIF+/- NOD breeding and cohoused in a 1:1 ratio. Recombinase-
activating-gene deficient NOD (Rag−/−NOD) mice or severe-combined-immunodeficient 
NOD (NOD.scid) mice and BDC2.5 NOD mice were originally obtained from the Jackson 
Laboratory. All mice used in this study were kept under specific pathogen–free conditions, in 
a 12-hour dark/light cycle and housed in individually-ventilated filter cages with free access to 
water and autoclaved food at the Yale University animal facility. The use of the animals in this 
study was approved by the Yale University Institutional Animal Care and Use Committee 
 2.2. Antibodies and reagents 
All the fluorochrome-conjugated mAbs used in this study were purchased from Biolegend or 
eBioscience unless otherwise stated. Supernatants from the hybridomas (2C11, GK1.5, 
TIB105, 10.2.16, 2.4G2) producing mAbs (to CD3, CD4, CD8, MHC-class II I-Ag7 and Fc 
receptor, respectively), used for cell purification or stimulation, were generously provided by 
the late Charles Janeway Jr. (Yale University). Magnetic beads conjugated with goat anti-
mouse IgG, goat anti-mouse IgM or goat anti-rat IgG were purchased from QIAGEN. RPMI-
1640 medium and heat-inactivated FCS were purchased from Invitrogen and Gemini, 
respectively 
2.3. Diabetes assessment 
Female wild-type (WT) NOD and TRIF−/−NOD mice were co-housed (littermates) or non-
cohoused for observation of diabetes development until 30 weeks of age. Mice were tested 
for glycosuria weekly and diabetes was confirmed by blood glucose ≥250 mg/dl 
(13.9 mmol/L). 
 
2.4. Adoptive transfer 
Total splenocytes (10 × 106 cells/mouse) from diabetic female donor mice (WT NOD or 
TRIF−/−NOD mice) were injected (i.v.) into 4-5-week-old immune-deficient female NOD 
(Rag−/−NOD or NOD.scid mice) or irradiated (600 rads) 4-5-week-old female WT NOD or 
TRIF−/−NOD mice. The recipient mice were monitored for the development of diabetes until 
120 days or 25 weeks post-injection 
 
2.5. Extraction of gut bacterial DNA 
Fecal samples were collected fresh from 3 month-old female cohoused or non-cohoused WT 
NOD and TRIF−/−NOD mice. Bacterial DNA was extracted as previously described [17]. 
Briefly, the fecal samples (∼15–25 mg/mouse) were re-suspended in 300 μl Tris-EDTA (TE) 
and incubated for one hour at 37 °C in the presence of 7.5 μl SDS (0.5%) and 3 μl Proteinase 
K (20 mg/ml). One volume of phenol:chloroform:isoamyl alcohol (25:24:1), 200 μl of 20% SDS 
and 0.3 g of zirconium/silica beads (0.1 mm, Biospec Inc) were added and samples were 
mixed with a Mini-bead-beater for 2 min. The sample was then mixed with 820 μl of 
phenol:chloroform:isoamyl alcohol (25:24:1), centrifuged and the aqueous layer collected into 
a new tube. The bacterial DNA was precipitated with 0.6 volume of isopropanol, washed with 
70% ethanol, air-dried and resuspended in 100 μl of sterile water.  
 
2.6. 16S rRNA sequencing, microbiota classification and functional composition 
prediction 
16S rRNA sequencing was performed as described previously [18]. Briefly, the V4 region of 
the bacterial 16S ribosomal gene was amplified from each DNA sample with barcoded 
broadly conserved bacterial primers (forward, 5′- CATGCTGCCTCCCGTAGGAGT-3'; 
reverse, 5′-TCAGAGTTTGATCCTGGCTCAG-3′). The PCR products were purified (QIAGEN 
gel extraction kit) and quantified (Nanodrop spectrophotometer), and equimolar amounts of 
each sample were pooled and pyrosequenced on an Ion Torrent Personal Genome Machine 
sequencing system (Life Technologies). The results were analyzed using the Quantitative 
Insights Into Microbial Ecology (QIIME) software package (version 1.8) and highly accurate 
Operational taxonomic unit sequences from microbial amplicon reads (UPARSE) pipeline 
(version 7.0). After removing the primer sequences, the sequences were de-multiplexed, 
quality-filtered using the Quantitative Insights into Microbial Ecology (QIIME) software, and 
further quality and chimera-filtered using the UPARSE pipeline algorithm [19]. Operational 
taxonomic units were picked with 97% identity in UPARSE pipeline. In QIIME, the 
Greengenes reference database was used for taxonomy assignment, which was performed 
at various levels using representative sequences of each operational taxonomic unit. β-
diversity was calculated to compare differences between microbial community profiles and 
the data is shown as Principal Coordinate Analysis (PCoA). The functional composition of the 
bacterial communities was predicted by Phylogenetic Investigation of Communities by 
Reconstruction of Unobserved States (PICRUSt) using the 16S rRNA sequencing data as 
outlined by Langille et al. [20]. Raw sequencing data of 16S rRNA genes from NOD and 
TRIF−/−NOD were deposited in the NCBI Sequence Read Archive (SRA) under BIOProject 
ID PRJNA394782 (SRR5849873). 
 
2.7. Fecal microbiota transfer 
Fecal samples from 2 to 4 month-old female NOD donor mice (non-diabetic) were 
resuspended in sterile PBS. Female TRIF−/−NOD mice (4 week-old) were gavaged weekly 
with 200 μl of the suspension (∼108 bacteria/mouse) until 30 weeks of age or diabetes onset. 
Recipient mice were screened weekly for diabetes development until 30 weeks of age 
 2.8. In vitro bacterial co-culture 
Large intestine and spleens were harvested from 2-month-old female WT NOD or TRIF−/ 
−NOD. Large intestines were flushed using 1 × PBS and pooled from 2 mice. The large 
intestinal flush was then centrifuged at low speed to remove dietary material (52 × g, 5 min) 
prior to a further centrifugation to remove tissue cells (454 × g, 5 min). Bacteria were isolated 
by high-speed centrifugation (1876 × g, 5 min) and resuspended in 1 × PBS. Bacterial 
concentration was measured with a spectrophotometer (Bio-rad) and 107 colony forming 
units (cfu)/ml were used to stimulate splenocytes (1 × 106) overnight (16 h) cultured in RPMI 
complete media; phorbol 12-myristate 13-acetate (PMA, 50 ng/ml, Sigma), Ionomycin 
(500 ng/ml, Sigma) and Golgi-plug (eBioscience) were added in the final 4-hour culture. 
 
2.9. Cell surface staining 
Briefly, splenocytes and lymph node cells from 3-month-old female WT NOD and 
TRIF−/−NOD mice were harvested. Single cell suspensions were generated and red blood 
cellswere lysed from the splenocytes. 1 × 106 cells were then incubated with a 2.4G2 Fc-
blocking antibody prior to staining with antibodies to CD4 (GK1.5), CD8α (53–6.7), CD11b 
(M1/70), CD11c (N418), CD19 (6D5), B220 (RA3-6B2), CD80 (16-10A1), CD44 (IM7), 
CD62L (MEL-14), CD69 (H1·2F3) and a viability dye (all from BioLegend). FoxP3 (FJK-16S, 
eBioscience) was stained after surface staining following the protocol from eBioscience. The 
samples were analyzed on a BD LSRII flow cytometer (BD Biosciences) 
 
2.10. Intracellular cytokine (ICC) assay 
ICC was performed according to the protocol from eBioscience. Briefly, splenocytes from 3-
month-old female WT NOD and TRIF−/−NOD mice were stimulated with PMA (50 ng/ml, 
Sigma) and ionomycin (500 ng/ml, Sigma) in the presence of Golgi-plug (eBioscience) for 4 h. 
The cells were then stained with antibodies to surface markers before fixation and 
permeabilization. Fc receptors were blocked with 2.4G2 Fc-blocking antibody before staining 
with fluorochrome-labeled antibodies to detect intracellular cytokines (IL-10 (JES5-16E3), IL-
6 (MP5-20F3), TNFα (MP6-XT22) and TGFβ (TW7-16B4); all from BioLegend). The samples 
were analyzed on a BD LSRII flow cytometer (BD Biosciences). 
 
2.11. Cell purification 
Splenic B cells, CD11b+ and CD11c+ cells were purified from 2 to 3-month-old female WT 
NOD and TRIF−/−NOD mice using the EasySep™ Mouse B Cell Isolation Kit, the EasySep™ 
Mouse CD11b Positive Selection Kit and the EasySep™ Mouse CD11c Positive Selection Kit 
(STEMCELL Technologies) respectively, according to the manufacturer's instructions. Total 
APC were enriched by depleting CD4+ and CD8+ T cells using hybridoma supernatants 
(anti-CD4, GK1.5 and anti-CD8, T1B105) and magnetic bead (conjugated with goat anti-rat 
IgG) separation as described previously [21]. BDC2.5 CD4+ T cells were purified from spleens 
of BDC2.5 NOD mice by depleting CD8+ T cells, MHC class II+ cells (anti-MHC II, 10.2.16) 
and B cells (anti-mouse IgM and IgG, QIAGEN), followed by goat anti-rat conjugated 
magnetic bead separation. Tregs (CD4+CD25+) were purified from 2-month-old female WT 
NOD and TRIF−/−NOD using EasySep™ Mouse CD4+CD25+ Regulatory T Cell Isolation Kit 
II from STEMCELL Technologies 
 
2.12. Generation of bone marrow-derived dendritic cells (BMDCs) 
BMDCs were generated from BM cells of 2-month-old female WT NOD and TRIF−/−NOD 
mice. The BM cells were cultured in the presence of granulocyte-macrophage colony-
stimulating factor (25 ng/ml) and IL-4 (25 ng/ml) in RPMI 1640 complete medium 
supplemented with 5% heat-inactivated FBS. Culture medium was replenished every 2 days. 
On day 5, adherent and loosely adherent cells were harvested. Approximately 70% of the 
cells were CD11c+ DCs by FACS analysis. 
 
2.13. Cell proliferation assay 
Either total splenocytes or purified splenic T cells from 2-month-old female WT NOD and 
TRIF−/−NOD mice were cultured in triplicate (105 cells/well) in the presence of different 
concentrations of anti-CD3 (2C11) and anti-CD28 (37.51, 1:300). 3H-thymidine was added 
during the last 18 h of a 4-d culture and T cell proliferation was assessed by 3H-thymidine 
incorporation as counts per minute (CPM). For antigen-specific T cell responses, purified 
splenic BDC2.5 CD4+ T cells were cultured with irradiated antigen presenting cells – either 
total splenocytes or purified BMDCs, splenic CD11c+, CD11b+ or B cells in the absence or 
presence of different concentrations of the BDC2.5 mimotope peptide (RTRPLWVRME) 
[22]. 3H-thymidine incorporation was determined as described earlier and the data were 
presented as the stimulation index (SI, the mean cpm in the presence of antigen/the mean 
cpm in the absence of antigen). 
 
2.14. Treg suppression assay 
Purified BDC2.5 CD4+ T cells were cultured with purified Tregs from 2-month-old female WT 
NOD or TRIF−/−NOD mice (1:1) in the presence of irradiated total splenocytes from WT NOD 
(as antigen-presenting cells, APCs) and mimotope peptide. BDC CD4+ T cells cultured with 
the irradiated APCs without mimotope peptide were used as a control. Treg suppression was 
determined by 3H-thymidine incorporation and the data are presented as the SI. 
 
2.15. Statistics 
Statistical analysis was performed using GraphPad Prism software version 7.0. Diabetes 
incidence was compared using the Log-rank or Gehan-Breslow-Wilcoxon test. In vitroassays 
were analyzed by single or multiple Student's t-test, with Bonferroni correction or Analysis of 
variance (ANOVA). P < 0.05 was considered significant. Analysis of similarities (ANOSIM) 
was used to analyze β-diversity of taxonomic families of gut microbiota 
 
 
3. RESULTS 
3.1. TRIF-deficiency protects NOD mice from type 1 diabetes development in a 
housing-dependent manner 
To understand if TRIF influences diabetes susceptibility, we generated TRIF-deficient 
(TRIF−/-) NOD mice by backcrossing TRIF−/-C57BL/6 mice to our NOD mice for over 10 
generations. We first observed the natural history of spontaneous diabetes development in 
WT NOD (TRIF+/+) and TRIF−/−NOD littermates when both genotypes were housed 
together (cohoused) or when housed by genotype (e.g. TRIF−/−NOD mice housed only with 
other TRIF−/−NOD mice, designated as non-cohoused). We found that TRIF−/−NOD female 
mice developed a similar incidence of diabetes to WT NOD mice when they were cohoused 
(Figure  1A). Interestingly, when TRIF−/−NOD mice were housed only with TRIF−/−NOD 
mice, diabetes development was significantly reduced compared to WT NOD mice (Figure  
1B). Together, the data suggested that the genotype of the cohoused mice influences the 
development of diabetes in TRIF−/−NOD mice, while this has no effect on diabetes 
development in WT NOD mice. 
 
3.2. TRIF deficiency alters the gut microbiota composition 
As TRIF is important in mediating downstream responses to pathogen associated molecular 
patterns (through TLR3 and partially through TLR4), we hypothesized that the gut 
microbiotamay influence the diabetes development of TRIF−/−NOD mice. To assess gut 
microbiota composition, we performed 16S rRNA sequencing using fresh fecal samples from 
cohoused and non-cohoused TRIF−/−NOD mice and WT NOD mice. 
 
PCoA analysis of the fecal samples identified that the gut microbiota were very different 
between non-cohoused TRIF−/−NOD and WT NOD mice as shown by the separate clustering 
of the samples (Figure  2A, red triangles and blue squares respectively). Interestingly, upon 
cohousing the mice, the gut microbiota were indistinguishable between TRIF-deficient and 
TRIF-sufficient mice (Figure  2A, green diamonds and maroon dots). The effect of housing 
had little impact on the gut microbiota of WT NOD mice, supporting the data in Figure  1, 
showing no differences in diabetes development. Therefore, our further analysis was focused 
on the mice that were non-cohoused (either TRIF−/−NOD or WT NOD mice), as these were 
significantly different to one another in both diabetes development and microbial composition. 
 
Investigation of the microbial composition revealed TRIF−/−NOD mice had a significant 
reduction of Proteobacteria in the gut microbiota, compared to WT NOD mice (Figure  2B). 
Further analysis revealed a significant reduction of relative abundance in Sutterella 
(Proteobacteria) at the genus and species level and a reduction of Rikenella (Bacteroidetes) 
at the species level in TRIF−/−NOD compared to WT NOD mice (Figure  2C and D). 
Furthermore, a significant expansion of Turicibacter species (Firmicutes) was found in 
TRIF−/−NOD mice compared to WT NOD (Figure  2D). To assess if the altered microbial 
composition also altered the function of the bacteria, we analyzed the sequence results with 
PICRUSt software [20]. As shown in Figure  2E, there was a significantly increased expression 
of ATP-binding cassette (ABC) transporter in the gut bacteria from TRIF−/−NOD mice. 
Together, our data illustrate that TRIF affects the composition and some functions of the gut 
microbiota in NOD mice. 
 
To test if diabetes protection in TRIF−/−NOD mice was indeed due to the altered gut 
microbiota, we performed fecal microbiota transfer experiments by gavaging TRIF−/−NOD 
mice with fecal microbiota from WT NOD mice and assessed the mice for diabetes 
development. Interestingly, merely transferring the gut microbiota from WT NOD reversed the 
diabetes protection in TRIF−/−NOD mice, which developed a very similar incidence of 
diabetes to WT NOD mice (Figure  2F). This result supports the role of the microbiota in 
mediating the disease protection seen in TRIF−/−NOD mice (Figure  1B). 
 
3.3. Gut microbiota alter the diabetogenic capability of immune cells 
To further investigate the effect of changes in the gut microbiota by TRIF on host immune 
phenotype and function, and thus diabetes susceptibility, we cultured splenocytes from 
TRIF−/−NOD or WT NOD mice with heat-killed gut microbiota from either WT or TRIF−/−NOD 
mice. Interestingly, we found that, compared to WT NOD microbiota, TRIF−/−NOD microbiota 
induced attenuated CD69 expression on splenic CD11c+ DCs, CD11b+ macrophages and B 
cells from both WT NOD and TRIF−/−NOD mice (Figure  3A). Furthermore, TRIF−/−NOD 
microbiota stimulated significantly fewer pro-inflammatory IL-6-producing CD11c+ DCs 
(Figure  3B), CD11b+ macrophages and B cells compared to WT microbiota. Proinflammatory 
cytokine (TNFα and IL-17)-expressing CD4+ T cells, regardless of the donor of the T cells, 
were also significantly lower when exposed to TRIF−/−NOD microbiota compared to WT NOD 
microbiota (Figure  3C and D). We also found TRIF−/−NOD microbiota induced fewer effector 
CD4+ T cells than WT NOD microbiota (Figure  3E). In line with the reduced percentage of 
effector CD4+ T cells, there was an increase in percentage of naïve CD4+ T cells when 
exposed to TRIF−/−NOD bacteria compared to WT NOD bacteria; however, this was only 
significant in CD4+ T cells from TRIF−/−NOD cells (Figure  3E). A similar increase in naïve 
CD8+ T cells was also seen when the CD4+ T cells, from both TRIF-deficient and -sufficient 
hosts, were co-cultured with TRIF−/ −NOD microbiota compared to WT NOD microbiota. A 
lower number of TNFα-producing CD8+ T cells in response to TRIF−/ −NOD microbiota were 
seen compared to the response to WT NOD microbiota although this was not statistically 
significant. No differences were seen in the cultures without bacteria, suggesting that 
microbial stimulation is required to mediate these phenotypic and functional changes. 
 
3.4. Impaired function of APCs in TRIF−/−NOD mice 
TRIF plays an important role in APC maturation [[23], [24], [25]] and we hypothesized that TRIF-
deficiency would affect the function of APCs and thus, contribute to the diabetes-protected 
phenotype seen in TRIF−/−NOD mice. We examined the phenotype and function of APCs 
from TRIF−/−NOD mice and found that TRIF−/−NOD mice had reduced CD80 expression on 
CD11c+ DCs compared to WT NOD mice, within both the pancreatic draining lymph 
nodes (PLN) and the Peyer's patches (PP, Figure  4A). Additionally, we found that DCs from 
TRIF−/−NOD mice had reduced production of the proinflammatory cytokines, IL-6 
and TNFα (Figure  4B and C) while exhibiting enhanced anti-inflammatory TGFβ production 
(Figure  4D) compared to TRIF-sufficient WT NOD mice. 
 
Next, we investigated the function of TRIF-deficient APCs in vitro and in vivo. We first tested 
the antigen-presenting capabilities of APCs from TRIF−/−NOD and TRIF+/+NOD mice by 
culturing diabetogenic BDC2.5 CD4+ T cells with the BDC2.5 mimotope peptide presented by 
mitomycin C-treated splenic APCs (T cell-depleted splenocytes). BDC2.5 CD4+ T cells were 
chosen as responder cells as they are potent diabetogenic T cells recognizing an 
islet autoantigen, which has recently been identified as a hybrid peptide of chromogranin A 
and insulin [26,27]. We found that TRIF-deficient APCs had significantly impaired antigen-
presenting function compared with TRIF-sufficient APCs (Figure  4E). To identify the role of 
different APC subsets, we purified splenic CD11b+, CD11c+ and CD19+ cells and conducted 
the same antigen presentation assay. We found that TRIF-deficient CD11c+ DCs were 
responsible for the impaired antigen presentation to BDC2.5 T cells (Figure  4F), as purified 
TRIF-deficient CD11b+ and CD19+ cells showed enhanced function. The impaired antigen 
presentation function was also found in TRIF-deficient bone marrow-derived DCs. We then 
tested APC function in vivo in an adoptive transfer system. We transferred purified T cells 
from diabetic WT NOD mice together with TRIF-deficient or -sufficient total APC into 
Rag−/−NOD mice. Consistent with the results from the experiments in vitro, we found that 
APCs from TRIF−/−NOD mice had an attenuated ability to facilitate diabetes development 
induced by diabetogenic T cells in the recipients compared to the APCs from TRIF-sufficient 
mice (Figure  4G). Together, these data suggest that TRIF is important for APC function in 
mediating diabetes susceptibility 
 
3.5. Reduced T cell activation and function in TRIF−/−NOD mice 
Having identified changes within the APC compartment, we asked if there were any TRIF-
related effects on the T cells. Interestingly, TRIF−/−NOD mice exhibited reduced T cell 
activation, as assessed by CD69 expression, in both CD4+ and CD8+ T cell subsets 
specifically within the PLNs (Figure  5A). Next, we tested whether TRIF expression 
influenced the T cell response to T cell receptor stimulation using anti-CD3 and anti-CD28. 
As shown in Figure  5B, TRIF-deficient T cells showed impaired proliferation in response to 
pan-T cell stimulation compared with TRIF-sufficient T cells. As the T cell response to anti-
CD3 stimulation requires the cross-linking of anti-CD3 molecules by APCs, to further probe 
whether the cause of impaired T cell proliferation was T cell intrinsic or secondary due to the 
impaired APC function, we cultured WT NOD T cells with either WT NOD APCs or TRIF−/ 
−NOD APCs and vice versa in the presence of anti-CD3. Interestingly, we found that TRIF-
deficiency affects the function of both T cells and APCs 
 
Next we investigated if Treg cells would be affected by the absence of TRIF expression. We 
found no difference in the Treg frequency or absolute number between WT NOD and 
TRIF−/−NOD mice. We also tested the function of the Treg cells in an antigen-specific Treg 
suppression assay, in which pathogenic BDC2.5 CD4+ T cells responder cells were cultured 
with purified splenic Tregs from WT or TRIF−/−NOD mice in the presence of antigenic peptide. 
It is interesting that TRIF-deficient Tregs showed stronger suppression of pathogenic 
responder cells than WT Tregs (Figure  5C) 
 
Our results indicated that TRIF-deficiency affected the function of both APCs and T cells 
including Tregs. To confirm that the changes seen in vitro contributed to diabetes 
protection in vivo, we performed a series of adoptive transfer experiments. Firstly, we 
adoptively transferred total splenocytes from WT or TRIF−/−NOD mice into Rag-deficient 
hosts. We found TRIF−/- splenocytes were significantly less able to induce diabetes compared 
to TRIF-sufficient counterparts (Figure  5D). Secondly, we transferred total splenocytes from 
WT NOD or TRIF−/−NOD mice into irradiated WT NOD (Figure  5E) and TRIF−/−NOD (Figure  
5F) recipients to ensure the protection was related to the immune system and not the non-
hematopoietic cells. In both cases we found TRIF-deficient splenocytes had significantly 
weaker ability to induce diabetes development in all the recipients (Figure  5E and F). Our 
data provide strong evidence that the TRIF-deficiency in the immune cells was responsible 
for the diabetes-protected phenotype in TRIF−/−NOD mice 
 
4. DISCUSSION 
TLRs and their adaptor molecule MyD88 are known to influence T1D development mediated 
by gut microbiota [3,10,13,15]. In this study, we investigated the role of TRIF, another key 
adaptor molecule, in T1D development in NOD mice. We found that TRIF deficiency resulted 
in a significant reduced diabetes development. Similar to MyD88-deficient NOD mice, in the 
absence of TRIF, diabetes protection is mediated through changes in the gut microbiome. 
However, unlike MyD88-deficient NOD mice, co-housing TRIF-deficient NOD mice with TRIF-
sufficient NOD mice was able to reverse diabetes protection in TRIF-deficient mice. Our 
results clearly demonstrate that the gut microbiota alter diabetogencity in these mice. 
However, TRIF deficiency not only alters the composition of gut microbiota but also alters the 
function of innate and adaptive immune cells. In the absence of TRIF, dendritic cells 
exhibited reduced costimulation, reduced inflammatory cytokine expression and impaired 
antigen-presenting function to diabetogenic CD4+ T cells. In the absence of TRIF, T cells 
were not able to mount an optimal response to anti-CD3 stimulation whereas Treg cells 
showed enhanced suppressive function in the absence of TRIF. Furthermore, diabetes 
protection could be maintained when transferring WT NOD T cells from a diabetic donor 
together with TRIF-deficient APCs or transferring TRIF-deficient splenocytes to TRIF-
sufficient or -deficient hosts. Our results revealed the inter-relationship between genetic 
factors and the gut microbiota, as the genetic deletion of TRIF changed the composition of 
gut microbiota leading to diabetes protection. However, this effect on gut microbiota and 
diabetes protection could be overridden by introducing gut microbiota from TRIF-sufficient 
NOD mice. Our results also demonstrated that TRIF plays a direct role in immune cell 
functions that are most likely to be independent of gut microbiota. 
 
Burrows and colleagues recently reported that TRIF-deficient NOD mice and TRIF-sufficient 
NOD mice developed a similar incidence of diabetes when co-housed [15], with which our 
results are consistent. However, the authors did not investigate the effect of non-cohousing 
the TRIF-deficient or TRIF-sufficient NOD mice on diabetes development. Instead, they 
studied the effect of TRIF on MyD88-mediated diabetes protection. It is interesting that the 
authors found that approximately 20% of TRIF and MyD88 double-deficient NOD mice 
developed diabetes at an old age (>25 weeks) whereas MyD88-deficient TRIF-sufficient NOD 
mice were diabetes free [15]. Although our study design and approaches were different to 
those of Burrows and colleagues, the conclusion is complementary. Both studies have shown 
that deficiency of innate immune molecules, such as TRIF, modulates T1D development and 
this effect is mediated by gut microbiota. In addition to the effect the innate immune system to 
change gut microbiota, we also demonstrated that the TRIF may play a direct role in the 
functions of innate and adaptive immune cells. 
 
Several studies in human T1D have also shown alterations in gut microbiota [[28], [29], [30]]. The 
changes include a reduction of diversity in the composition of gut microbiota but an increased 
relative abundance of some gut bacterial species in patients with T1D compared to healthy 
individuals [28,[31], [32], [33], [34]]. Recent studies also indicate that gut bacterial products can 
modify T1D development in both humans [30] and NOD mice [18,35]. In our current study, we 
found a significantly reduced relative abundance of Sutterella (Proteobacteria) in TRIF-
deficient mice that are protected from T1D development. Sutterellareside within the human 
intestine and are reported to be associated with Crohn's disease [36,37] and other health 
issues [38]. Interestingly, Turicibacter was significantly increased in diabetes-protected TRIF-
deficient NOD mice. Turicibacter has been placed in the class of Erysipelotrichia and been 
reported to be associated with the TNBS-induced colitis mouse model [39] and obesity in 
humans [40]. Thus, it is clear that the composition of gut microbiota plays an important role in 
health and disease. 
 
Given the microbial differences seen between TRIF−/−NOD and WT NOD mice, we further 
investigated their functional profile using PICRUSt [20]. We found that gut microbiota from 
TRIF−/−NOD mice have an increased relative abundance of bacteria with ABC transporters 
compared to WT NOD mice. ABC transporters are a large superfamily, conserved between 
bacteria and humans. They are vital for the survival and function of prokaryotic or eukaryotic 
cells. It is not clear how ABC transporter-expressing gut bacteria affect the immune cells and 
T1D protection in TRIF−/−NOD mice. However, stimulating the immune cells with gut 
microbiota from TRIF−/−NOD mice, but not from WT NOD mice, reduced CD69 expression on 
the three major types of antigen presenting cells – dendritic cells, macrophages and B cells. 
Interestingly, CD69 expression on dendritic cells is important in regulating the migration of 
dendritic cells [41]. As DCs sample microbial antigens from the gut lumen [42], it is conceivable 
that the microbial products including metabolites in TRIF−/−NOD mice suppress CD69 
expression on DCs, which in turn limits DC migration to the islets to initiate autoinflammation. 
It is also possible that through a similar mechanism, gut microbiota from TRIF−/−NOD mice 
induce lower levels of proinflammatory cytokines (IL-6, TNFα and IL-17) by DC and CD4+ T 
cells regardless of the TRIF expression. It is noteworthy that a significantly lower frequency of 
IL-6-expressing DCs was induced in both the in vitrobacterial co-culture assays and in ex 
vivo ICC assays, emphasizing the direct influence of gut microbiota from TRIF−/−NOD mice. 
Increasing evidence from human studies indicates an alteration of gut microbiota in patients 
with T1D compared to healthy control subjects [[28], [29], [30]], but less is known about the 
immune cell response to the different microbiota. Our results indicate that the microbiota from 
diabetes-protected hosts suppress the proinflammatory cytokine milieu that is important in 
promoting autoimmunity. Our results also highlight the importance of dendritic cell-microbiota 
interactions in shaping the development of autoimmunity. 
Studies in both mice and humans have shown that TGFβ induces Treg differentiation and/or 
conversion in the periphery [43]. We observed a higher frequency of TGFβ-producing DCs 
when TRIF was deficient; TRIF-deficient Tregs also exhibited stronger immune suppressive 
function, both of which likely contributed to disease protection in this model. Interestingly, 
T1D patients had reduced TGFβ in the circulation [44]. 
 
It is known that the development and maturation of the immune system is dependent on 
the commensal bacteria [45]. Our results provide further evidence that commensal gut bacteria 
can shape the diabetogenicity of immune cells. By changing the constituent mice housed 
together, we can alter the composition of microbiota and are able to reverse the diabetes-
protective effect seen in non-cohoused TRIF-deficient NOD mice. Interestingly, the altered 
gut microbiota in TRIF-deficient NOD mice did not confer diabetes protection on TRIF-
sufficient NOD mice, which suggests a requirement for TRIF deficiency in the host immune 
cells, in addition to the altered microbiota for the diabetes-protected phenotype to manifest. 
 
In conclusion, our study provides evidence that innate immunity modifies the composition of 
the gut microbiota, which in turn regulates autoimmune diabetes development. In the 
absence of TRIF, NOD mice harbor altered gut microbiota, leading to a reduced 
proinflammatory phenotype and function of immune cells that are associated with diabetes 
protection. However, this protective effect, which is mediated by TRIF-deficiency, can be 
reversed by introducing gut microbiota from TRIF-sufficient NOD mice. Our study also 
provides further evidence of the interaction between the genes and the gut microbiota, which 
is important for mediating immune tolerance (or lack of tolerance). Lastly, our results also 
demonstrate that innate immunity can affect T cell function directly. Further studies are 
required not only to identify the specific bacterial strain(s) that promote immune tolerance but 
also the molecular mechanism by which non-pathogenic gut bacteria regulate the function of 
immune cells. The more we understand mechanistically, the greater the potential for 
therapeutic applications which will help in designing new therapies for T1D to reduce disease 
severity or even prevent the disease by modulation of the gut microbiota. 
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Figure  1.  
 
 
 
TRIF-deficiency protects NOD mice from diabetes development and is dependent on gut 
microbiota. The natural history of diabetes development was observed in female WT NOD 
and TRIF−/−NOD until 30–32 weeks. (A) Diabetes incidence of cohoused (mixed genotype) 
female WT NOD and TRIF−/−NOD littermates. (B) Diabetes incidence of non-cohoused (non-
mixed genotype) female WT NOD and TRIF−/−NOD mice. Data were pooled from at least two 
independent experiments. Log-rank test for survival was used for analysis of diabetes 
incidence. 
 
 
 
 
 
 
 
 
  
Figure  2.  
 
 
 
TRIF deficiency alters the gut microbiota in NOD mice. Fecal samples from female WT NOD and 
TRIF−/−NOD mice were used for taxonomic analysis by 16S rRNA sequencing. (A) PCoA plot showing 
β-diversity. ANOSIM was used for statistical analysis. Significant taxonomic compositions of the gut 
microbiota of non-cohoused WT NOD and TRIF−/−NOD mice were shown by as phylum (B), genus (C) 
and species (D). (E) Predictive functional profiling illustrating increased expression of ABC 
transporter in TRIF−/−NOD mice. (F) Diabetes incidence from TRIF−/−NOD mice that were gavaged with 
a suspension of NOD feces (NOD FT) compared with incidence in WT NOD and TRIF−/−NOD mice. 
The functional composition of the metagenome of the bacteria communities was predicted using 
PICRUSt. Multiple t tests with Bonferroni correction were used for statistical analysis in (B–D) while a 
two-tailed Student's t-test was used for statistical analysis in (E) and a log-rank (mantel-cox) test was 
used in (F). 
 
 
 
 
 
 
 
  
Figure  3.  
 
 
 
Direct effect of gut microbiota on immune cells. Splenocytes (106 cells/ml) of 2-month-old female WT 
NOD or TRIF−/−NOD mice were incubated overnight (16 h) with gut bacteria (107 cfu/ml) isolated from 
large intestinal contents of WT NOD or TRIF−/−NOD mice, and the cells were stained with mAb for 
surface markers and ICC. For ICC staining, the splenocytes were also further stimulated with PMA and 
ionomycin in the presence of Golgi plug for the final 4 h (A) CD69-expressing CD11c+ cells. (B) IL-6 
expressing CD11c+ cells. (C) TNF-α expressing CD4+ T cells. (D) IL-17A-expressing CD4+ T cells. (E) 
CD4+ T cell subsets (Left: CD44+CD62L−; right: CD44−CD62L+). Two-tailed Student's t-test was used for 
statistical analysis from (A–E). 
 
 
  
Figure  4. 
 
 
 
Impaired APC function and attenuated activation of CD11c+ DCs in TRIF−/−NOD mice. (A) Percentage 
of CD80-expressing CD11c+ DCs. Immune cells from spleen, PLN, MLN and PP of 2-month-old female 
WT NOD and TRIF−/−NOD mice were stained with fluorochrome-conjugated anti-CD11c, anti-CD80, 
anti-CD11b, anti-B220 and anti-TCRβ antibodies. Representative FACS plots are shown on the left and 
the summary of CD80-expressing CD11c+ DCs is shown on the right. Data are shown as mean ± SEM. 
The experiment was repeated more than three times. (B–D): Splenocytes from 2-month-old female WT 
NOD and TRIF−/−NOD mice were stimulated with PMA and ionomycin in the presence of Golgi plug 
followed by ICC staining. (B) IL-6; (C) TNF-α and (D) TGF-β. Data are shown as mean ± SEM and 
pooled from two independent experiments. (E) Proliferation of BDC2.5 CD4+ T cells. Purified NOD 
BDC2.5 CD4+ T cells were cultured with irradiated T cell-depleted splenocytes from 2-month-old female 
WT NOD and TRIF−/−NOD mice in the presence of mimotope peptide. Proliferation was assessed 
using 3H-thymidine incorporation. n = 3–5/mice/group/experiments from more than three experiments. 
(F) Proliferation of BDC2.5 CD4+ T cells. Purified NOD BDC2.5 CD4+ T cells were cultured with 
irradiated splenic CD11c+ DCs from 2-month-old female WT NOD and TRIF−/−NOD mice in the presence 
of mimotope peptide. Data were pooled from two independent experiments. (G) Diabetes incidence 
following adoptive transfer. Purified splenic T cells (7 × 106 cells/mouse) from diabetic WT NOD mice 
were i.v. injected into Rag−/−NOD or NOD.scid mice with T cell-depleted splenic APCs 
(7 × 106 cells/mouse) from either female WT NOD or TRIF−/−NOD mice. Data were pooled from two 
independent experiments. Log-rank test for survival was used for analysis of diabetes incidence. Two-
way ANOVA was used for the comparison in (E) and (F). Two-tailed Student's t-test was used for 
statistical analysis in (B–D). 
 
 
  
Figure  5.  
 
 
Reduced T cell activation and function in TRIF−/−NOD mice. (A) CD69-expressing CD4+ and CD8+T 
cells in TRIF−/−NOD mice. FACS plots for PLNs are shown on the left and the summary of CD69-
expressing CD4+ and CD8+ T cells are shown on the right. One of three independent experiments is 
presented, with data shown as mean ± SEM. (B) BDC CD4+ T cell proliferation. Purified splenic CD4+ T 
cells from BDC2.5 mice were cocultured with total splenocytes from either female WT NOD or 
TRIF−/−NOD mice on stimulation by anti-CD3/anti-CD28. This experiment was repeated more than three 
times. (C) Treg suppression assay. Purified Treg (CD4+CD25+ cells) from 2-month-old female WT NOD 
or TRIF−/−NOD mice were cultured with BDC2.5 CD4+ T cells (1:1) in the presence of irradiated WT NOD 
splenocytes in the presence of BDC2.5 mimotope peptide. Data are shown as SI. 
(D) Diabetes incidence following adoptive transfer. Total splenocytes (8 × 106 cells/mouse) from 
female diabetic WT NOD or TRIF−/−NOD mice were injected i.v. into immune-deficient NOD mice 
(Rag−/−NOD or NOD.scid mice) for observation of diabetes incidence. Data were pooled from two 
independent experiments. Total splenocytes (8 × 106 cells/mouse) from female diabetic WT NOD or 
TRIF−/−NOD mice were injected i.v.into sub-lethally irradiated 4-5 week-old female WT NOD (E) or 
TRIF−/−NOD (F) mice followed by observation for development of diabetes. Data were pooled from 2 to 
3 independent experiments. Two-tailed Student's t-test was used for statistical analysis in (A) and (C) 
Two-way ANOVA was used for the comparison in (B). Log-rank test for survival was used for analysis 
of diabetes incidence in (D–F). 
 
 
 
 
 
